EGFR mutation in Middle East and Africa is it really lower than in asiatic NSCLC ?

Date 24 November 2018
Event ESMO Asia 2018 Congress
Session Poster display - Cocktail
Topics Cancer Biology
Pathology/Molecular Biology
Presenter Zineb Benbrahim
Citation Annals of Oncology (2018) 29 (suppl_9): ix150-ix169. 10.1093/annonc/mdy425
Authors Z. Benbrahim, H. Bedoudou, N. Mellas
  • Medical Oncology, Hassan II University Hospital, 30000 - Fez/MA



Epidermal growth factor receptor (EGFR) mutations are potential therapeutic targets leading to improved response and progression free survival with EGFR tyrosine kinase inhibitors in NSCLC. Some studies have demonstrated a genetic divergence of EGFR mutation rates according to ethnicity with highest frequencies reported in Asian populations (47%). In this study, we conducted a systematic review of publications related to the frequency of the EGFR mutation in Middle East and African regions to compare the results with those of asian populations.


We used PubMed and the Cochrane Library databases to conduct a literature search using the terms “[EGFR] AND [mutation] AND [Non Small Cell Lung Cancer] AND [Middle East OR Africa].” We assessed studies published in English and French from 2004 until 2016.


Ten relevant studies were included in this systematic review. Overall, 1215 patients with non-small cell lung cancer (NSCLC) were included in this analysis. The overall ratio of male to female patients was 2.15. Of total patients included, 41.1% had never smoked and 85.8% had been diagnosed with adenocarcinoma. In 8 of the 10 studies, polymerase chain reaction (PCR) analyses were conducted to identify EGFR mutations. In total, 257 patients had an EGFR mutation, corresponding to a prevalence of 21.2%. The most frequent abnormality detected in all of the studies was in exon 19. In addition, all studies concluded the presence of a correlation between EGFR mutation status and female sex, non-smoking status, and adenocarcinoma subtype.


The EGFR mutation frequency in Middle East and African patients is higher than that shown in white populations but still lower than the frequency reported in Asian NSCLC populations.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Zineb Benbrahim.


Has not received any funding.


All authors have declared no conflicts of interest.